Decoy Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.8M |
| Operating income | -$12.6M | -$5.7M | -$12.9M | -$31.8M | -$12.8M |
| Operating expenses | $12.6M | $5.7M | $12.9M | $31.8M | $14.7M |
| Cash from operations | -$4.8M | -$4.5M | -$12.8M | -$17.6M | -$10.2M |
| Capital expenditure | $577,000 | $0 | — | — | $0 |
| Free cash flow | -$5.4M | -$4.5M | — | — | -$10.2M |
| Impairments | $0 | $0 | $0 | $8.9M | $0 |
| Total assets | $11.1M | $3.0M | $6.6M | $14.7M | $40.8M |
| Total liabilities | $5.2M | $1.5M | $1.3M | $4.3M | $2.1M |
Shares outstanding 532.0K · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.